RVMD vs TNGX
RVMD: A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital. TNGX: A precision oncology company utilizing a proprietary functional genomics platform to discover and develop targeted, synthetic-lethal cancer therapies.
Side-by-side fundamentals
| Metric | RVMD | TNGX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $183.03 | $28.10 | |
| Market cap as of 2026-07-23 | $39.0B | $4.6B | |
| PEG as of 2026-07-23 | -0.34 | n/a | |
| Net margin as of 2026-07-23 | -2833.9% | -151.2% | TNGX higher |
| Operating margin as of 2026-07-23 | -3145.0% | -165.9% | TNGX higher |
| ROE as of 2026-07-23 | -54.1% | -41.5% | TNGX higher |
| ROA as of 2026-07-23 | -39.1% | -33.4% | TNGX higher |
| Debt / equity as of 2026-07-23 | 0.19 | 0.00 | TNGX lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +39.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +35.9% | |
| Beta as of 2026-07-23 | 1.41 | 1.12 | |
| 1-year return as of 2026-07-22 close | +378.3% | +328.7% | RVMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.